# Ruxolitinib for Premalignant Breast Disease

> **NCT02928978** · PHASE2 · COMPLETED · sponsor: **Julie Nangia** · enrollment: 84 (actual)

## Conditions studied

- Ductal Carcinoma In Situ
- Atypical Lobular Hyperplasia
- Atypical Ductal Hyperplasia
- Lobular Carcinoma In Situ

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Placebo (for Ruxolitinib)

## Key facts

- **NCT ID:** NCT02928978
- **Lead sponsor:** Julie Nangia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-13
- **Primary completion:** 2024-08-29
- **Final completion:** 2024-09-18
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02928978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02928978, "Ruxolitinib for Premalignant Breast Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02928978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*